New imaging agent targets lung cancer cells in early trial
NCT ID NCT07500987
First seen Apr 05, 2026 · Last updated May 13, 2026 · Updated 5 times
Summary
This early-stage study tests a new imaging drug, [111In]-FPI-2107, in 12 Chinese adults with a specific type of lung cancer (EGFR mutation-positive NSCLC). The goal is to see if it is safe and how it spreads in the body, not to treat the cancer. Participants receive the drug and then have scans to measure radiation and tumor uptake.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR MUTATION-POSITIVE NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGBeijing, 100142, China
-
Research Site
RECRUITINGShandong, China
-
Research Site
RECRUITINGWuhan, 430022, China
Conditions
Explore the condition pages connected to this study.